Venture Capital 101: A Primer on Venture Capital
Monday, October 22, 2018 at 12:00pm to 1:30pm
Building E25, 111
45 CARLETON ST, Cambridge, MA 02142
So you have a stellar idea and are ready to start a company--now what? Where do you turn to find funding?
In this free seminar, experts from Osage University Partners (OUP), a venture capital firm focused on investing in startups that are commercializing pioneering university technologies, will give you practical insights on how to engage with VCs and other funders so you can get your startup up and running.
Join the MIT TLO and OUP to hear from Matt Cohen (Principal, Life Science) and Manny Stockman (Senior Associate, Tech) on essential questions every startup should consider, including:
Does your newco have what it takes to secure VC financing?
Who is investing in academic startups?
What technology sectors are most likely to get funded?
How should you and your colleagues approach potential investors?
When should you seek funding from non-dilutive sources, family and friends, angels, crowdfunding?
Who should be the CEO?
The event is free and open to the MIT community. A free lunch and Q&A session will take place in E25-119/121 after the seminar concludes.
ABOUT OSAGE UNIVERSITY PARTNERS
Osage University Partners (OUP) partners with top research universities to invest in their most innovative startups, and OUP shares its investment profit with its partner institutions. The firm invests in software, hardware, and life science companies at all stages of company development. OUP has partnered with over 90 universities, including 39 of the top 50 U.S. institutions by research expenditures, and has invested in over 80 of their spinouts. OUP is part of a family of investment funds within Osage Partners, which is based in Philadelphia, PA and manages in excess of $500 million.
Matt Cohen, Principal, Life Science
Matt is a Principal at Osage University Partners where he focuses on Life Science investments. He is a board observer at Faraday Pharma, PMV Pharma, Arrakis Therapeutics, Spero Therapeutics, and Capella Bioscience. Prior to joining Osage, Matt was a strategy consultant with L.E.K. Consulting serving clients in biopharma, diagnostics, research tools, healthcare, and private equity. As a Ph.D. student at the University of Pennsylvania, Matt conducted research on the antibody response to a novel protein-based poxvirus vaccine and advised several startups while working with the Penn Biotech Group. Matt holds a Ph.D. in Cell and Molecular Biology from The University of Pennsylvania, and a B.S. in Microbiology from The Pennsylvania State University.
Manny Stockman, Senior Associate, Tech
Manny joined Osage University Partners in 2015. At Osage, he has focused on core technology areas across software, computing, and IoT companies like PsiKick, SiFive, Infinite Uptime, and IonQ. Prior to joining Osage, Manny was at Lockheed Martin ATL and Skunkworks. He led a team of engineers executing on the transition of early stage technologies into the defense industry by joining universities with industry to develop unique technology solutions across the materials, applied physics and photonics domains. Manny holds a Ph.D. from Princeton University in Aerospace Engineering and Applied Physics and a B.S.E in Mechanical Engineering from Duke University.